Published in Exp Ther Med on June 20, 2011
The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS One (2013) 1.06
Prognostic significance of MTOR pathway component expression in neuroendocrine tumors. J Clin Oncol (2013) 1.02
Expression of phosphorylated mTOR and its clinical significances in small cell lung cancer. Int J Clin Exp Pathol (2015) 0.82
Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours. Oncol Rep (2012) 0.80
Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study. Oncol Lett (2017) 0.75
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Regulation of translation initiation by FRAP/mTOR. Genes Dev (2001) 9.40
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
Drosophila S6 kinase: a regulator of cell size. Science (1999) 6.76
mTOR, translation initiation and cancer. Oncogene (2006) 4.68
mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol (2005) 3.24
Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol (1998) 2.93
Carcinoid tumors. Oncologist (2008) 2.86
FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem (2000) 2.72
Bronchopulmonary neuroendocrine tumors. Cancer (2008) 2.69
Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol (2006) 2.11
Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet (1997) 1.70
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med (2004) 1.40
Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol (2006) 1.39
Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol (2007) 1.31
Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer (2008) 1.30
Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther (2002) 1.20
Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer (1999) 1.16
Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol (2006) 1.09
The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest (2001) 1.03
AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res (2009) 1.02
Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer (2010) 1.00
Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells. J Am Coll Surg (2009) 1.00
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Relat Cancer (2010) 0.97
Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer (2009) 0.92
Prognostic markers in patients with typical bronchial carcinoid tumors. J Clin Endocrinol Metab (2000) 0.90
Diffuse panbronchiolitis with multiple tumorlets. A quantitative study of the Kultschitzky cells and the clusters. Acta Pathol Jpn (1985) 0.82
Quantitative expansion of structural genomic alterations in the spectrum of neuroendocrine lung carcinomas. J Pathol (2002) 0.82
Pulmonary tumourlets and microcarcinoids in bronchiectasis. Monaldi Arch Chest Dis (1997) 0.78
Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol (2008) 3.55
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res (2002) 3.33
Robot-aided thoracoscopic thymectomy for early-stage thymoma: a multicenter European study. J Thorac Cardiovasc Surg (2012) 2.30
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res (2003) 2.26
Surgical treatment of non-small cell lung cancer in octogenarians. Interact Cardiovasc Thorac Surg (2011) 2.16
Elective surgery for giant bullous emphysema: a 5-year clinical and functional follow-up. Chest (2005) 2.10
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol (2010) 1.97
Robotic lobectomy for non-small cell lung cancer (NSCLC): long-term oncologic results. J Thorac Cardiovasc Surg (2011) 1.94
Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann Thorac Surg (2005) 1.75
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab (2010) 1.68
Mechanical prevention of distal embolization during primary angioplasty: safety, feasibility, and impact on myocardial reperfusion. Circulation (2003) 1.68
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res (2003) 1.55
Distal embolization during primary angioplasty: histopathologic features and predictability. Am Heart J (2005) 1.47
Surgical treatment of pleural recurrence from thymoma. Eur J Cardiothorac Surg (2008) 1.46
A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg (2006) 1.45
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res (2002) 1.43
Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res (2005) 1.35
Robotically assisted lobectomy: learning curve and complications. Thorac Surg Clin (2008) 1.33
Surgical treatment of recurrent thymomas. J Thorac Oncol (2010) 1.26
Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Res (2004) 1.25
Sleeve and wedge parenchyma-sparing bronchial resections in low-grade neoplasms of the bronchial airway. J Thorac Cardiovasc Surg (2007) 1.22
Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol (2007) 1.22
Long-term results of radiofrequency ablation treatment of stage I non-small cell lung cancer: a prospective intention-to-treat study. J Thorac Oncol (2011) 1.15
Association of thymoma and myasthenia gravis: oncological and neurological results of the surgical treatment. Eur J Cardiothorac Surg (2009) 1.12
Robotic renal transplantation: first European case. Transpl Int (2010) 1.11
Radio-guided thoracoscopic surgery (RGTS) of small pulmonary nodules. Surg Endosc (2011) 1.10
WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin Cancer Res (2007) 1.06
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res (2005) 1.04
Thoracoscopic localization techniques for patients with solitary pulmonary nodule: hookwire versus radio-guided surgery. Eur J Cardiothorac Surg (2007) 1.04
Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features. Int J Oncol (2013) 1.03
ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Arch Pathol Lab Med (2014) 1.03
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer (2014) 1.02
High level of messenger RNA for BRMS1 in primary breast carcinomas is associated with poor prognosis. Int J Cancer (2007) 1.01
Primary neuroendocrine tumors of the thymus: a multicenter experience of 35 patients. Ann Thorac Surg (2012) 1.01
Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica (2010) 1.00
Percutaneous radiofrequency ablation of lung tumours: results in the mid-term. Eur J Cardiothorac Surg (2006) 1.00
Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg (2002) 1.00
Neoadjuvant chemotherapy for stage III and IVA thymomas: a single-institution experience with a long follow-up. J Thorac Oncol (2006) 0.99
Ten-year experience of mediastinal robotic surgery in a single referral centre. Eur J Cardiothorac Surg (2012) 0.98
Polymorphisms within inflammatory genes and colorectal cancer. J Negat Results Biomed (2006) 0.98
Management of pleural recurrence after curative resection of thymoma. J Thorac Cardiovasc Surg (2008) 0.97
Metachronous adrenal masses in resected non-small cell lung cancer patients: therapeutic implications of laparoscopic adrenalectomy. Eur J Cardiothorac Surg (2005) 0.97
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci U S A (2007) 0.96
Cyclin A and E2F1 overexpression correlate with reduced disease-free survival in node-negative breast cancer patients. Anticancer Res (2007) 0.95
Cyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapy. Cancer Sci (2009) 0.94
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. Oncol Rep (2009) 0.93
Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. J Thorac Oncol (2011) 0.93
Radiofrequency ablation of lung malignancies: where do we stand? Cardiovasc Intervent Radiol (2004) 0.93
Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol (2011) 0.93
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. Pharmacogenet Genomics (2006) 0.93
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol (2006) 0.93
Malignancies within rhinophyma: report of three new cases and review of the literature. Aesthetic Plast Surg (2011) 0.92
Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. Int J Biol Markers (2010) 0.91
Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. Cancer Cytopathol (2014) 0.90
Robotic extended thymectomy for early-stage thymomas. Eur J Cardiothorac Surg (2012) 0.89
Thermal ablation of lung tissue: in vivo experimental comparison of microwave and radiofrequency. Cardiovasc Intervent Radiol (2010) 0.89
An "inflammatory" mitochondrial myopathy. A case report. Neuromuscul Disord (2013) 0.88
Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. Eur J Cancer (2005) 0.88
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Target Oncol (2013) 0.88
Magnetic carbon nanotubes: a new tool for shepherding mesenchymal stem cells by magnetic fields. Nanomedicine (Lond) (2011) 0.88
DeltaN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region. Hum Mutat (2010) 0.88
Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR. Lung Cancer (2004) 0.88
Massive pneumoencephalus of late onset after an en bloc resection for lung cancer. J Thorac Cardiovasc Surg (2004) 0.87
BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features. Thyroid (2010) 0.87
All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes. J Clin Endocrinol Metab (2004) 0.87
PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data. Neuromuscul Disord (2011) 0.86
Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma. Hum Pathol (2008) 0.86
Video robotic lobectomy. Multimed Man Cardiothorac Surg (2005) 0.86